{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:40:42Z","timestamp":1707525642094},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,14]]},"DOI":"10.7759\/cureus.52267","type":"journal-article","created":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T18:58:05Z","timestamp":1705258685000},"source":"Crossref","is-referenced-by-count":0,"title":["Cerebral Tuberculosis After Therapy With Adalimumab for Hidradenitis Suppurativa: A Rare Case"],"prefix":"10.7759","author":[{"given":"Francisca","family":"Martins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Fonseca Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Malheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Cerqueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice. Hidradenitis suppurativa","volume":"366","author":"Jemec GB","year":"2012","unstructured":"Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012, 366:158-64. 10.1056\/NEJMcp1014163","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat R","year":"2020","unstructured":"Sabat R, Jemec GB, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020, 6:18. 10.1038\/s41572-020-0149-1","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen TV","year":"2021","unstructured":"Nguyen TV, Damiani G, Orenstein LA, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021, 35:50-61. 10.1111\/jdv.16677","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7339","article-title":"A review of the current landscape of hidradenitis suppurativa treatment development","volume":"22","author":"Westerkam L","year":"2023","unstructured":"Westerkam L, Sayed C. A review of the current landscape of hidradenitis suppurativa treatment development. J Drugs Dermatol. 2023, 22:1021-6. 10.36849\/JDD.7339","journal-title":"J Drugs Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073753","article-title":"New and emerging targeted therapies for hidradenitis suppurativa","volume":"23","author":"Markota \u010cagalj A","year":"2022","unstructured":"Markota \u010cagalj A, Marinovi\u0107 B, Bukvi\u0107 Mokos Z. New and emerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci. 2022, 23:3753. 10.3390\/ijms23073753","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-9-6","article-title":"Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil","volume":"11","author":"Rivitti-Machado MC","year":"2022","unstructured":"Rivitti-Machado MC, Ferreira Magalh\u00e3es R, Souto da Silva R, Duarte GV, Bosnich FZ, Tunala RG, Forestiero FJ. Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil. Drugs Context. 2022, 11:10.7573\/dic.2021-9-6","journal-title":"Drugs Context"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1734560","article-title":"Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa","volume":"19","author":"Tzanetakou V","year":"2020","unstructured":"Tzanetakou V, Stergianou D, Giamarellos-Bourboulis EJ. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa. Expert Opin Drug Saf. 2020, 19:381-93. 10.1080\/14740338.2020.1734560","journal-title":"Expert Opin Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S391356","article-title":"Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience","volume":"16","author":"Martora F","year":"2023","unstructured":"Martora F, Megna M, Battista T, et al.. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023, 16:135-48. 10.2147\/CCID.S391356","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach DR","year":"2002","unstructured":"Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002, 168:4620-7. 10.4049\/jimmunol.168.9.4620","journal-title":"J Immunol"},{"key":"ref10","unstructured":"World Health Organization. Global tuberculosis report 2022. (2022). https.\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2022."},{"key":"ref11","unstructured":"Tuberculosis surveillance and monitoring report in Portugal. definitive data for 2021. National Tuberculosis Program, March 2023. (Article in Portuguese). (2023). https:\/\/www.dgs.pt\/documentos-e-publicacoes\/relatorio-de-vigilancia-e-monitorizacao-da-tuberculose-em-portugal-dados-...."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)","volume":"24","author":"Winthrop KL","year":"2018","unstructured":"Winthrop KL, Mariette X, Silva JT, et al.. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018, 24:S21-40. 10.1016\/j.cmi.2018.02.002","journal-title":"Clin Microbiol Infect"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball AB","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al.. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016, 375:422-34. 10.1056\/NEJMoa1504370","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.20344\/amp.15625","article-title":"Guideline for the treatment and prevention of infections associated with immunosuppressive therapy for autoimmune diseases. (Article in Portuguese)","volume":"34","author":"Valdoleiros SR","year":"2021","unstructured":"Valdoleiros SR, Furtado I, Silva C, et al.. Guideline for the treatment and prevention of infections associated with immunosuppressive therapy for autoimmune diseases. (Article in Portuguese). Acta Med Port. 2021, 34:469-83. 10.20344\/amp.15625","journal-title":"Acta Med Port"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0044-2017","article-title":"Central nervous system tuberculosis","volume":"5","author":"Leonard JM","year":"2017","unstructured":"Leonard JM. Central nervous system tuberculosis. Microbiol Spectr. 2017, 5:10.1128\/microbiolspec.TNMI7-0044-2017","journal-title":"Microbiol Spectr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.29021\/spdv.70.4.97","article-title":"Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy","volume":"37","author":"Duarte R","year":"2012","unstructured":"Duarte R, Campainha S, Cotter J, et al.. Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy. Acta Reumatol Port. 2012, 37:253-9. 10.29021\/spdv.70.4.97","journal-title":"Acta Reumatol Port"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2017.10.009","article-title":"Tuberculosis in immunosuppressed patients","volume":"36","author":"Machuca I","year":"2018","unstructured":"Machuca I, Vidal E, de la Torre-Cisneros J, Rivero-Rom\u00e1n A. Tuberculosis in immunosuppressed patients. Enferm Infecc Microbiol Clin (Engl Ed). 2018, 36:366-74. 10.1016\/j.eimc.2017.10.009","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019190109","article-title":"Extrapulmonary tuberculosis: pathophysiology and imaging findings","volume":"39","author":"Rodriguez-Takeuchi SY","year":"2019","unstructured":"Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Extrapulmonary tuberculosis: pathophysiology and imaging findings. Radiographics. 2019, 39:2023-37. 10.1148\/rg.2019190109","journal-title":"Radiographics"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.carj.2016.10.007","article-title":"Central nervous system tuberculosis: an imaging perspective","volume":"68","author":"Chaudhary V","year":"2017","unstructured":"Chaudhary V, Bano S, Garga UC. Central nervous system tuberculosis: an imaging perspective. Can Assoc Radiol J. 2017, 68:161-70. 10.1016\/j.carj.2016.10.007","journal-title":"Can Assoc Radiol J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203436","article-title":"Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-\u03b1 antagonist therapy","volume":"68","author":"Singanayagam A","year":"2013","unstructured":"Singanayagam A, Manalan K, Sridhar S, et al.. Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-\u03b1 antagonist therapy. Thorax. 2013, 68:955-61. 10.1136\/thoraxjnl-2013-203436","journal-title":"Thorax"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/211954-cerebral-tuberculosis-after-therapy-with-adalimumab-for-hidradenitis-suppurativa-a-rare-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:00Z","timestamp":1707509520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/211954-cerebral-tuberculosis-after-therapy-with-adalimumab-for-hidradenitis-suppurativa-a-rare-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,14]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.52267","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,14]]}}}